TELA Bio, which sells soft tissue implants used in hernia repair and reconstructive surgery, raised $52 million by offering 4 million shares at $13, below the range of $14 to $16, to command a fully diluted market value of $142 million. TELA Bio plans to list on the Nasdaq under the symbol TELA. Jefferies and Piper Jaffray acted as lead managers on the deal.
The article Micro-cap medical device firm TELA Bio prices IPO at $13, below the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.